Production (Stage)
Aldeyra Therapeutics, Inc.
ALDX
$2.22
-$0.03-1.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 54.23% | -47.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.10% | 2.73% | |||
| Operating Income | 37.10% | -2.73% | |||
| Income Before Tax | 37.19% | -4.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37.19% | -4.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.19% | -4.60% | |||
| EBIT | 37.10% | -2.73% | |||
| EBITDA | 37.22% | -2.73% | |||
| EPS Basic | 37.50% | -4.49% | |||
| Normalized Basic EPS | 37.52% | -4.47% | |||
| EPS Diluted | 37.50% | -4.49% | |||
| Normalized Diluted EPS | 37.52% | -4.47% | |||
| Average Basic Shares Outstanding | 0.52% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.52% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||